Danaher (DHR) Corporate presentation summary

Financial performance and profile

• Achieved $24.6B in total revenue for 2025, with gross profit margin at 59.2% and adjusted operating profit margin at 28.2%.

• Generated over $5B in free cash flow, with strong recurring revenue streams across biotechnology, life sciences, and diagnostics.

• Net debt to adjusted EBITDA ratio improved to ~2.5x by 2025, indicating significant capital deployment capacity.

• Core sales growth for 2025 was 2.0%, with total sales growth at 3.0%.

• Outperformed S&P 500 and S&P Healthcare indices over 10, 15, and 25 years, with 2,063% total shareholder return over 25 years.

Strategic positioning and growth drivers

• Holds leading positions in fast-growing end markets, with ~80% recurring revenue and differentiated business models.

• Portfolio aligned to secular growth drivers: aging population, shift to biologics, monoclonal antibody proliferation, and adoption of new technologies.

• Bioprocessing revenue exceeds $6B, with over 80% from monoclonal antibodies and >90% of global mAb production volume supported.

• Life sciences and diagnostics segments each generated $7.3B and $10.0B in 2025 revenue, respectively, with strong global brands and high recurring revenue.

• Diagnostics segment benefits from molecular diagnostics penetration, automation, and decentralization of healthcare.

Innovation and operational excellence

• Invests in breakthrough innovation, such as advanced mass spectrometry, scalable bioreactors, and high-sensitivity immunoassay analyzers.

• Drives advances in neurodegenerative disease detection and treatment, enabling earlier Alzheimer's diagnosis and efficient biologics production.

• The Danaher Business System (DBS) underpins execution, focusing on continuous improvement, customer focus, and shareholder value.

• Approximately 25% increase in new product revenue generated over the last year.